De CVCT 2002 :

* AP Maggioni, B Darne, D Atar, E Abadie, B Pitt, F Zannad, on behalf of the participants in the 5th CardioVascular Clinical Trialists Workshop : FDA and CPMP Rulings on Subgroup Analyses. Cardiology 2007;107:97-102.    
 
* R Shah, B Darne, D Atar, E Abadie, KF Adams, F Zannad, on behalf of the participants in the 5th CardioVascular Clinical Trialists Workshop : Pharmacogenomics in cardiovascular clinical trials. Fundamental & Clinical Pharmacology 18 (2004) 705-708.

de CVCT 2004 :

* P Sleight, H Pouleur, and F Zannad : Benefits, Challenges, and registerability of the polypill. Eur H J (2006) 27, 1651-1656.

* SM Haffner, L Ruilope, B Dahlöf, E Abadie, S Kupfer, and F Zannad : Metabolic Syndrome, New Onset Diabetes, and New Endpoints in Cardiovascular Trials. Cardiovasc Pharmacol volume 47, Number 3, March 2006.

de CVCT 2005 :

* RM Lewis, DJ Gordon, PA Poole-Wilson, JS Borer, F Zannad : Similarities and Differences in Design Considerations  for Cell Therapy and Pharmacology Clinical Trials in Cardiovascular Indications. Cardiol 2008;110:73-80.

* W Gattis Stough, F Zannad, B Pitt, S Goldstein : Globalization of Cardiovascular Clinical Research : The Balance Between Meeting Medical Needs and Maintaining Scientific Standards. Am Heart J, August 2007;154:232-8.

* F Zannad, W Gattis Stough, JGF Cleland, NL Geller, C Torp-Pedersen, BA Kirwan, B Pitt, F Follath : Heart Failure as an Endpoint in Heart Failure and Non Heart Failure CardioVascular Clinical Trials : The Need for a Consensus Definition. Eur Heart J. 2008 Feb;29(3):413-421.

* JS. Borer, H Pouleur, E Abadie, F Follath, J Wittes, MA. Pfeffer, B Pitt, and F Zannad : Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. Eur Heart J (2007) 28, 1904–1909.

de CVCT 2006 :

* Borer JS, Gordon DJ, Geller NL. When should data and safety monitoring committees share interim results in cardiovascular trials? JAMA. 2008 Apr 9;299(14):1710-2.

 * J Cohn , JGF Cleland, J Lubsen , JS Borer, PG Steg , M Perelman, F Zannad : Unconventional endpoints in cardiovascular clinical trials:  should we be moving away from morbidity and mortality? J Card Fail. 2009 Apr;15(3):199-205